We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Case report: Slipped capital femoral epiphysis: a rare adverse event associated with FGFR tyrosine kinase inhibitor therapy in a child.
- Authors
Brizini, Meziane; Drimes, Tina; Bourne, Catherine; Streilein, Jessica; Drapeau, Annie; Wrogemann, Jens; Archer, Lori Anne; Del Bigio, Marc; Vanan, Magimairajan Issai
- Abstract
We report a case of slipped capital femoral epiphysis (SCFE), an on target skeletal toxicity of a pan-FGFR TKI inhibitor, erdafitinib. A 13-year-old boy was diagnosed to have an optic pathway/hypothalamic glioma with signs of increased intracranial pressure and obstructive hydrocephalus requiring placement of ventriculo-peritoneal (VP) shunt. Sequencing of the tumor showed FGFR1-tyrosine kinase domain internal tandem duplication (FGFR1-KD-ITD). He developed hypothalamic obesity with rapid weight gain and BMI >30. At 12 weeks of treatment with erdafitinib, he developed persistent knee pain. X-ray of the right hip showed SCFE. Erdafitinib was discontinued, and he underwent surgical pinning of the right hip. MRI at discontinuation of erdafitinib showed a 30% decrease in the size of the tumor, which has remained stable at 6 months follow-up. Our experience and literature review suggest that pediatric patients who are treated with pan-FGFR TKIs should be regularly monitored for skeletal side effects.
- Subjects
FEMORAL epiphysis; PROTEIN-tyrosine kinase inhibitors; LITERATURE reviews; FIBROBLAST growth factor receptors; HYDROCEPHALUS; KNEE pain; NEUROFIBROMATOSIS 1
- Publication
Frontiers in Oncology, 2024, p1
- ISSN
2234-943X
- Publication type
Article
- DOI
10.3389/fonc.2024.1399356